Catalog No.
VME43202
Species reactivity
Mouse
Host species
Rat
Isotype
IgG1, kappa
Clonality
Monoclonal
Target
Ox40, CD134, Txgp1, OX40 antigen, OX40L receptor, Tumor necrosis factor receptor superfamily member 4, Tnfrsf4
Concentration
1 mg/ml
Endotoxin level
< 1 EU/mg as determined by LAL test.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Applications
ELISA, In vivo OX40 Activation, WB
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
OX-86
Recognition of different subsets of alloreactive T cells by activation-induced markers., PMID:40204006
Activation of immune checkpoint OX40 inhibits HBV replication in a mouse model., PMID:39923582
Tumor-Infiltrating Immune Cells and HLA Expression as Potential Biomarkers Predicting Response to PD-1 Inhibitor Therapy in Stage IV Melanoma Patients., PMID:39766316
A Phase I Clinical Trial Adding OX40 Agonism to In Situ Therapeutic Cancer Vaccination in Patients with Low-Grade B-cell Lymphoma Highlights Challenges in Translation from Mouse to Human Studies., PMID:39745391
SHR-1806, a robust OX40 agonist to promote T cell-mediated antitumor immunity., PMID:39543823
Making the effect visible - OX40 targeting nanobodies for in vivo imaging of activated T cells., PMID:39474429
From structural design to delivery: mRNA therapeutics for cancer immunotherapy., PMID:38855617
The Role of OX40-OX40L Axis in the Pathogenesis of Atopic Dermatitis., PMID:38700255
Regulation of the Function of T Follicular Helper Cells and B Cells in Type 1 Diabetes Mellitus by the OX40/OX40L Axis., PMID:38625053
An OX-Tra'Ordinary Tale: The Role of OX40 and OX40L in Atopic Dermatitis., PMID:38607026
OX40/OX40 ligand and its role in precision immune oncology., PMID:38526805
OX40 in the Pathogenesis of Atopic Dermatitis-A New Therapeutic Target., PMID:38236520
Agonistic Bivalent Human scFvs-Fcγ Fusion Antibodies to OX40 Ectodomain Enhance T Cell Activities against Cancer., PMID:38140230
SARS-CoV-2 Variants Omicron BA.4/5 and XBB.1.5 Significantly Escape T Cell Recognition in Solid-organ Transplant Recipients Vaccinated Against the Ancestral Strain., PMID:38012843
BAT6026, a novel anti-OX40 antibody with enhanced antibody dependent cellular cytotoxicity effect for cancer immunotherapy., PMID:37576888
Assessing SARS-CoV-2-specific T-cell reactivity in late convalescents and vaccinees: Comparison and combination of QuantiFERON and activation-induced marker assays, and relation with antibody status., PMID:37220145
Impaired tolerance to the autoantigen LL-37 in acute coronary syndrome., PMID:37051254
The combination of oxaliplatin and anti-PD-1 inhibitor promotes immune cells infiltration and enhances anti-tumor effect of PD-1 blockade in bladder cancer., PMID:36960067
First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1)., PMID:36927527
Multicentric IL-5-positive Castleman Disease With Nephrotic Syndrome Relapsed After Rituximab Treatment., PMID:36593046
In Situ Reprogramming of Tumors for Activating the OX40/OX40 Ligand Checkpoint Pathway and Boosting Antitumor Immunity., PMID:35653749
Patients with treated indolent lymphomas immunized with BNT162b2 have reduced anti-spike neutralizing IgG to SARS-CoV-2 variants, but preserved antigen-specific T cell responses., PMID:35607995
Antigen-Specific CD4+ T-Cell Activation in Primary Antibody Deficiency After BNT162b2 mRNA COVID-19 Vaccination., PMID:35237272
Approaches of the Innate Immune System to Ameliorate Adaptive Immunotherapy for B-Cell Non-Hodgkin Lymphoma in Their Microenvironment., PMID:35008305
Anti-tumour effect of in situ vaccines combined with VEGFR inhibitors in the treatment of metastatic cervical cancer., PMID:34717193
A Phase I, Open-Label, Dose-Escalation Study of the OX40 Agonist Ivuxolimab in Patients with Locally Advanced or Metastatic Cancers., PMID:34615725
Immune Assessment of BNT162b2 m-RNA-Spike Based Vaccine Response in Adults., PMID:34440072
New Biologics for the Treatment of Atopic Dermatitis: Analysis of Efficacy, Safety, and Paradoxical Atopic Dermatitis Acceleration., PMID:34195265
Generation and characterization of a high-affinity chimeric anti-OX40 antibody with potent antitumor activity., PMID:33792041
Prolactin Increases the Frequency of Follicular T Helper Cells with Enhanced IL21 Secretion and OX40 Expression in Lupus-Prone MRL/lpr Mice., PMID:33763492
Immunogenicity risk assessment for biotherapeutics through in vitro detection of CD134 and CD137 on T helper cells., PMID:33729092
Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design., PMID:33682447
Anticancer immunity induced by a synthetic tumor-targeted CD137 agonist., PMID:33500260
Pro-inflammatory dopamine-2 receptor-specific T cells in paediatric movement and psychiatric disorders., PMID:33425355
Head-to-head study of oxelumab and adalimumab in a mouse model of ulcerative colitis based on NOD/Scid IL2Rγnull mice reconstituted with human peripheral blood mononuclear cells., PMID:33293281
OX40 Agonist BMS-986178 Alone or in Combination With Nivolumab and/or Ipilimumab in Patients With Advanced Solid Tumors., PMID:33148673
Targeting co-stimulatory molecules in autoimmune disease., PMID:32939077
FcγRIIB engagement drives agonistic activity of Fc-engineered αOX40 antibody to stimulate human tumor-infiltrating T cells., PMID:32900860
Visualization of Activated T Cells by OX40-ImmunoPET as a Strategy for Diagnosis of Acute Graft-versus-Host Disease., PMID:32900772
Structural basis for the interaction of human herpesvirus 6B tetrameric glycoprotein complex with the cellular receptor, human CD134., PMID:32678833
New and Emerging Systemic Treatments for Atopic Dermatitis., PMID:32519223
Randomized, Ascending Dose, Phase 2 Study of KHK4083, an Anti-OX40 Monoclonal Antibody, in Moderately Active Ulcerative Colitis., PMID:36776497
New pathways in immune stimulation: targeting OX40., PMID:32392177
A Combination of Radiotherapy, Hyperthermia, and Immunotherapy Inhibits Pancreatic Tumor Growth and Prolongs the Survival of Mice., PMID:32326142
gp96 Is Critical for both Human Herpesvirus 6A (HHV-6A) and HHV-6B Infections., PMID:32295911
The OX40 Axis is Associated with Both Systemic and Local Involvement in Atopic Dermatitis., PMID:32176307
Development and characterization of a novel anti-OX40 antibody for potent immune activation., PMID:32078015
No Evidence for Circulating Retina Specific Autoreactive T-cells in Latent Tuberculosis-associated Uveitis and Sarcoid Uveitis., PMID:31913737
CD137 Co-Stimulation Improves The Antitumor Effect Of LMP1-Specific Chimeric Antigen Receptor T Cells In Vitro And In Vivo., PMID:31807014
Cancer combinatorial immunotherapy using anti-OX40 agonist and anti-PD-L1 antagonist: a patent evaluation of US2018256711A1., PMID:31216214
For research use only. Not for human or drug use.
